Key result
Administration of 3 mg/kg of PR5 before coronary occlusion significantly reduced the incidence of ventricular fibrillation (43% vs 93%, P<0.05) and mortality (0% vs 47%, P<0.05) in rats.
Population
Rat models of myocardial ischaemia and reperfusion injury
Comparison
N-hydroxyguanidine compound PR5 administered… vs Controls
Design
Preclinical
Follow-up
Up to 120 minutes of reperfusion
Authors
Loading...
PR5 shows antiarrhythmic potential in rat ischemia models; leaves open translation to human cardioprotection pending clinical trials.
Absolute Event Rate: 43% vs 93%
p-value: p=<0.05
The N-hydroxyguanidine compound PR5 provides significant protection against ischaemia/reperfusion-induced myocardial necrosis and life-threatening arrhythmias in rat models.
Vēveris et al. (1999) studied Myocardial ischaemia and reperfusion injury. N-hydroxyguanidine PR5 vs. Controls was evaluated on Ventricular fibrillation incidence (p=<0.05). Administration of 3 mg/kg of PR5 before coronary occlusion significantly reduced the incidence of ventricular fibrillation (43% vs 93%, P<0.05) and mortality (0% vs 47%, P<0.05) in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: